Willis Investment Counsel’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$48.2M Buy
1,717,937
+4,473
+0.3% +$119K 2.63% 6
2025
Q4
$42.7M Buy
1,713,464
+9,824
+0.6% +$248K 2.2% 9
2025
Q3
$43.4M Sell
1,703,640
-15,018
-0.9% -$371K 2.37% 7
2025
Q2
$41.7M Buy
1,718,658
+196,230
+13% +$4.58M 2.44% 9
2025
Q1
$38.6M Buy
1,522,428
+103,590
+7% +$2.71M 2.59% 8
2024
Q4
$37.6M Buy
1,418,838
+121,632
+9% +$3.3M 2.47% 10
2024
Q3
$37.5M Buy
1,297,206
+6,966
+0.5% +$203K 2.44% 10
2024
Q2
$36.1M Buy
1,290,240
+70,173
+6% +$1.93M 2.5% 8
2024
Q1
$33.9M Buy
1,220,067
+43,568
+4% +$1.21M 2.33% 11
2023
Q4
$33.9M Buy
1,176,499
+106,048
+10% +$3.21M 2.38% 10
2023
Q3
$35.5M Buy
1,070,451
+47,517
+5% +$1.68M 2.69% 8
2023
Q2
$37.5M Buy
1,022,934
+55,732
+6% +$2.17M 2.45% 6
2023
Q1
$39.5M Buy
967,202
+84,963
+10% +$3.67M 2.58% 6
2022
Q4
$45.2M Buy
882,239
+61,361
+7% +$2.94M 2.89% 3
2022
Q3
$35.9M Sell
820,878
-71,319
-8% -$3.47M 2.61% 4
2022
Q2
$46.8M Sell
892,197
-2,511
-0.3% -$128K 2.87% 3
2022
Q1
$46.3M Sell
894,708
-18,472
-2% -$958K 2.45% 8
2021
Q4
$53.9M Sell
913,180
-175,792
-16% -$8.71M 2.84% 5
2021
Q3
$46.8M Buy
1,088,972
+19,855
+2% +$880K 2.68% 7
2021
Q2
$41.9M Buy
1,069,117
+49,188
+5% +$1.91M 2.47% 11
2021
Q1
$37M Sell
1,019,929
-16,795
-2% -$596K 2.24% 14
2020
Q4
$38.2M Sell
1,036,724
-42,787
-4% -$1.57M 2.61% 7
2020
Q3
$37.6M Buy
1,079,511
+191
+0% +$6.7K 3.37% 2
2020
Q2
$33.5M Sell
1,079,320
-11,651
-1% -$396K 2.6% 3
2020
Q1
$33.8M Sell
1,090,971
-1,249
-0.1% -$42.6K 2.8% 5
2019
Q4
$40.6M Buy
1,092,220
+1,520
+0.1% +$54.1K 2.63% 3
2019
Q3
$37.2M Buy
1,090,700
+234,012
+27% +$8.51M 2.49% 4
2019
Q2
$35.2M Buy
856,688
+447,947
+110% +$17.8M 2.38% 4
2019
Q1
$12.3M Sell
408,741
-357,452
-47% -$14.3M 0.85% 53
2018
Q4
$31.7M Sell
766,193
-36,295
-5% -$1.51M 2.36% 3
2018
Q3
$33.6M Sell
802,488
-57,280
-7% -$2.21M 2.31% 4
2018
Q2
$29.6M Buy
859,768
+1,829
+0.2% +$62.5K 2.18% 4
2018
Q1
$28.9M Sell
857,939
-77,790
-8% -$2.67M 2.23% 5
2017
Q4
$32.2M Buy
935,729
+7,727
+0.8% +$263K 2.26% 5
2017
Q3
$31.4M Buy
928,002
+15,932
+2% +$512K 2.27% 4
2017
Q2
$29.1M Buy
912,070
+2,561
+0.3% +$80.8K 2.2% 4
2017
Q1
$29.5M Buy
909,509
+8,093
+0.9% +$255K 2.21% 4
2016
Q4
$27.8M Buy
901,416
+111,493
+14% +$3.4M 2.07% 5
2016
Q3
$25.4M Buy
789,923
+34,689
+5% +$1.16M 2.03% 4
2016
Q2
$25.2M Sell
755,234
-26,051
-3% -$831K 2.15% 5
2016
Q1
$22M Buy
781,285
+7,456
+1% +$213K 1.93% 7
2015
Q4
$23.7M Buy
773,829
+78,586
+11% +$2.47M 2.16% 5
2015
Q3
$20.7M Buy
695,243
+25,274
+4% +$810K 2.03% 5
2015
Q2
$21.3M Sell
669,969
-88,756
-12% -$2.89M 2.03% 5
2015
Q1
$25M Buy
758,725
+97,279
+15% +$3.09M 2.32% 3
2014
Q4
$19.5M Buy
661,446
+964
+0.1% +$27.6K 1.83% 9
2014
Q3
$18.5M Sell
660,482
-4,227
-0.6% -$119K 1.95% 6
2014
Q2
$18.7M Buy
664,709
+77,352
+13% +$2.2M 1.83% 8
2014
Q1
$17.9M Sell
587,357
-31
-0% -$924 1.81% 9
2013
Q4
$17.1K Buy
587,388
+17,422
+3% +$507K 0.79% 13
2013
Q3
$15.1M Hold
569,966
1.73% 12
2013
Q2
$15.1M Buy
+569,966
New +$15.7M 1.73% 12

Other funds holding PFE

Willis Investment Counsel's PFE Position: Q1 2026 in Review

Willis Investment Counsel increased its Pfizer (PFE) stake by 0.26% in Q1 2026, buying an estimated $119K and bringing the position to 1,717,937 shares worth $48.2M. The position accounts for 2.63% of the portfolio, ranked #6.

Willis Investment Counsel first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $53.9M in Q4 2021. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Willis Investment Counsel held 1,717,937 shares of Pfizer worth $48.2M as of Q1 2026.
  • Willis Investment Counsel bought 4,473 Pfizer shares in Q1 2026, an estimated $119K.
  • Pfizer made up 2.63% of Willis Investment Counsel's portfolio in Q1 2026, its #6 holding.
  • Willis Investment Counsel first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Willis Investment Counsel's Pfizer position peaked at $53.9M in Q4 2021.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Willis Investment Counsel's 13F filing for Q1 2026, filed 5 May 2026.